Natriuretic peptides are excellent discriminators of risk and their utilization to guide the additional therapy, particularly SGLT-2 inhibitors, in order to reduce heart failure in type 2 diabetes at the earliest possible stages (96). Here, SLC5A2 is linked to heart failure.